Editorial: Bivalirudin versus unfractionated heparin in acute myocardial infarction: Why are we
still debating? - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe …

Bivalirudin, a direct thrombin inhibitor, was developed as an antithrombin agent for patients
undergoing percutaneous coronary interventions (PCI) with the hypothesis that it would …

Background The aim of this study was to assess the impact of bivalirudin, as compared to
unfractionated heparin, on clinical outcomes in patients with ST‐segment elevation …

Background Conflicting evidence exists on the efficacy and safety of bivalirudin
administered as part of percutaneous coronary intervention (PCI) in patients with an acute …

Introduction and objectives Contrasting data have been reported on bivalirudin as an
anticoagulation strategy during percutaneous coronary interventions, offering theoretical …

Background The comparative efficacy of various anticoagulation strategies has not been
clearly established in patients with acute myocardial infarction who are undergoing …

Background The registry-based randomized VALIDATE-SWEDEHEART trial compared
bivalirudin vs. heparin in patients undergoing percutaneous coronary intervention (PCI) for …

Background The registry-based randomized VALIDATE-SWEDEHEART trial
(NCT02311231) compared bivalirudin vs. heparin in patients undergoing percutaneous …

Methods: We systematically searched Ovid MEDLINE, Ovid Embase, Ovid Cochrane
Database of Systematic Reviews, Scopus, and Web of Science from database inception in …

Unfractionated heparin (UFH) currently represents the standard of care for patients with
acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) …